The effect of obesity on in-hospital mortality among patients with COVID-19 receiving corticosteroids
Copyright © 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved..
BACKGROUND AND AIMS: Obesity has been reported to be one of the most frequent comorbidities in COVID-19 patients and associated with higher rates of in-hospital mortality compared to non-obese patients. Acute kidney injury (AKI) is also known to be a complication associated with obesity in critically-ill COVID-19 patients. We aimed to investigate whether obesity was associated with increased risk of in-hospital mortality and AKI among patients with COVID-19 treated with corticosteroids.
METHODS: We utilized 9965 hospitalized COVID-19 patient data and divided patients who were treated with corticosteroids into 6 groups by body mass index (BMI) (less than 18.5, 18.5-25, 25-30, 30-35, 35-40, 40 kg/m2 or greater). The association between BMI and in-hospital mortality and between BMI and incidence rate of AKI during admission among COVID-19 patients receiving corticosteroids were retrospectively investigated.
RESULTS: There were 4587 study participants receiving corticosteroids (mean age 66.5 ± 15.5 years, men 56.6%, mean BMI 29.0 ± 7.2 kg/m2). The smooth spline curve suggested a J-shape association between BMI and in-hospital mortality. Patients with BMI above 40 kg/m2 exhibited a higher in-hospital mortality and higher incidence rate of AKI during admission compared to patients with BMI between 25 and 30 kg/m2. The differences in in-hospital mortality and the rate of AKI were larger among patients with severe COVID-19.
CONCLUSIONS: Class III obesity was associated with high in-hospital mortality and AKI in patients with COVID-19 treated by corticosteroids. Clinicians must stay vigilant on the impact of class III obesity and development of AKI to disease trajectory of COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Diabetes & metabolic syndrome - 16(2022), 1 vom: 28. Jan., Seite 102373 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
So, Matsuo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute kidney injury |
|---|
| Anmerkungen: |
Date Completed 25.02.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dsx.2021.102373 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335148050 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335148050 | ||
| 003 | DE-627 | ||
| 005 | 20231225225212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dsx.2021.102373 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335148050 | ||
| 035 | |a (NLM)34979344 | ||
| 035 | |a (PII)S1871-4021(21)00393-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a So, Matsuo |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effect of obesity on in-hospital mortality among patients with COVID-19 receiving corticosteroids |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.02.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: Obesity has been reported to be one of the most frequent comorbidities in COVID-19 patients and associated with higher rates of in-hospital mortality compared to non-obese patients. Acute kidney injury (AKI) is also known to be a complication associated with obesity in critically-ill COVID-19 patients. We aimed to investigate whether obesity was associated with increased risk of in-hospital mortality and AKI among patients with COVID-19 treated with corticosteroids | ||
| 520 | |a METHODS: We utilized 9965 hospitalized COVID-19 patient data and divided patients who were treated with corticosteroids into 6 groups by body mass index (BMI) (less than 18.5, 18.5-25, 25-30, 30-35, 35-40, 40 kg/m2 or greater). The association between BMI and in-hospital mortality and between BMI and incidence rate of AKI during admission among COVID-19 patients receiving corticosteroids were retrospectively investigated | ||
| 520 | |a RESULTS: There were 4587 study participants receiving corticosteroids (mean age 66.5 ± 15.5 years, men 56.6%, mean BMI 29.0 ± 7.2 kg/m2). The smooth spline curve suggested a J-shape association between BMI and in-hospital mortality. Patients with BMI above 40 kg/m2 exhibited a higher in-hospital mortality and higher incidence rate of AKI during admission compared to patients with BMI between 25 and 30 kg/m2. The differences in in-hospital mortality and the rate of AKI were larger among patients with severe COVID-19 | ||
| 520 | |a CONCLUSIONS: Class III obesity was associated with high in-hospital mortality and AKI in patients with COVID-19 treated by corticosteroids. Clinicians must stay vigilant on the impact of class III obesity and development of AKI to disease trajectory of COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute kidney injury | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Obesity | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Takahashi, Mai |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamoto, Yoshihisa |e verfasserin |4 aut | |
| 700 | 1 | |a Ishisaka, Yoshiko |e verfasserin |4 aut | |
| 700 | 1 | |a Iwagami, Masao |e verfasserin |4 aut | |
| 700 | 1 | |a Tsugawa, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Egorova, Natalia N |e verfasserin |4 aut | |
| 700 | 1 | |a Kuno, Toshiki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes & metabolic syndrome |d 2007 |g 16(2022), 1 vom: 28. Jan., Seite 102373 |w (DE-627)NLM189445564 |x 1878-0334 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:1 |g day:28 |g month:01 |g pages:102373 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dsx.2021.102373 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 1 |b 28 |c 01 |h 102373 | ||